Royal Bank of Canada
ANIK icon

Royal Bank of Canada’s Anika Therapeutics ANIK Stock Holding History

Royal Bank of Canada’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Sell
356
-459
-56% -$5.33K ﹤0.01% 6400
2025
Q4 		$8K Buy
815
+261
+47% +$2.5K ﹤0.01% 6508
2025
Q3 		$5K Sell
554
-25,015
-98% -$239K ﹤0.01% 6678
2025
Q2 		$271K Sell
25,569
-1,811
-7% -$22.9K ﹤0.01% 4929
2025
Q1 		$412K Sell
27,380
-15,629
-36% -$260K ﹤0.01% 4133
2024
Q4 		$707K Sell
43,009
-6,017
-12% -$119K ﹤0.01% 3814
2024
Q3 		$1.21M Sell
49,026
-135
-0.3% -$3.5K ﹤0.01% 3384
2024
Q2 		$1.25M Buy
49,161
+1,049
+2% +$27.2K ﹤0.01% 3266
2024
Q1 		$1.22M Sell
48,112
-4,086
-8% -$98.9K ﹤0.01% 3294
2023
Q4 		$1.18M Buy
52,198
+2,406
+5% +$49.8K ﹤0.01% 3531
2023
Q3 		$928K Sell
49,792
-877
-2% -$18.2K ﹤0.01% 3497
2023
Q2 		$1.32M Buy
50,669
+5,482
+12% +$147K ﹤0.01% 3156
2023
Q1 		$1.3M Buy
45,187
+16,122
+55% +$480K ﹤0.01% 3150
2022
Q4 		$861K Sell
29,065
-10,749
-27% -$306K ﹤0.01% 3614
2022
Q3 		$947K Sell
39,814
-798
-2% -$18.4K ﹤0.01% 3506
2022
Q2 		$907K Buy
40,612
+1,377
+4% +$30.7K ﹤0.01% 3592
2022
Q1 		$984K Sell
39,235
-3,520
-8% -$107K ﹤0.01% 3651
2021
Q4 		$1.53M Buy
42,755
+304
+0.7% +$12.2K ﹤0.01% 3401
2021
Q3 		$1.81M Buy
42,451
+1,115
+3% +$45.9K ﹤0.01% 3156
2021
Q2 		$1.79M Buy
41,336
+562
+1% +$23.9K ﹤0.01% 3164
2021
Q1 		$1.66M Sell
40,774
-10,734
-21% -$407K ﹤0.01% 3146
2020
Q4 		$2.33M Buy
51,508
+1,141
+2% +$43.3K ﹤0.01% 2784
2020
Q3 		$1.78M Buy
50,367
+447
+0.9% +$16.1K ﹤0.01% 2778
2020
Q2 		$1.88M Buy
49,920
+1,460
+3% +$48.1K ﹤0.01% 2670
2020
Q1 		$1.4M Buy
48,460
+2,483
+5% +$100K ﹤0.01% 2767
2019
Q4 		$2.38M Sell
45,977
-2,577
-5% -$150K ﹤0.01% 2742
2019
Q3 		$2.67M Sell
48,554
-28,092
-37% -$1.44M ﹤0.01% 2528
2019
Q2 		$3.11M Buy
76,646
+25,827
+51% +$942K ﹤0.01% 2420
2019
Q1 		$1.54M Buy
50,819
+8,208
+19% +$281K ﹤0.01% 2881
2018
Q4 		$1.43M Sell
42,611
-2,133
-5% -$77K ﹤0.01% 2882
2018
Q3 		$1.89M Buy
44,744
+3,143
+8% +$124K ﹤0.01% 2879
2018
Q2 		$1.33M Sell
41,601
-7,155
-15% -$295K ﹤0.01% 3016
2018
Q1 		$2.42M Buy
48,756
+2,030
+4% +$115K ﹤0.01% 2543
2017
Q4 		$2.52M Sell
46,726
-686
-1% -$38K ﹤0.01% 2547
2017
Q3 		$2.75M Buy
47,412
+7,462
+19% +$390K ﹤0.01% 2418
2017
Q2 		$1.97M Sell
39,950
-471
-1% -$21.7K ﹤0.01% 2595
2017
Q1 		$1.76M Buy
40,421
+2,658
+7% +$127K ﹤0.01% 2642
2016
Q4 		$1.85M Buy
37,763
+776
+2% +$35.9K ﹤0.01% 2649
2016
Q3 		$1.77M Sell
36,987
-1,343
-4% -$66.3K ﹤0.01% 2637
2016
Q2 		$2.06M Buy
38,330
+12,224
+47% +$576K ﹤0.01% 2521
2016
Q1 		$1.17M Sell
26,106
-11,704
-31% -$475K ﹤0.01% 2916
2015
Q4 		$1.44M Buy
37,810
+198
+0.5% +$7.57K ﹤0.01% 2801
2015
Q3 		$1.2M Buy
37,612
+310
+0.8% +$10.8K ﹤0.01% 2708
2015
Q2 		$1.23M Buy
37,302
+10,171
+37% +$363K ﹤0.01% 2712
2015
Q1 		$1.12M Buy
27,131
+1,000
+4% +$40.4K ﹤0.01% 2771
2014
Q4 		$1.06M Buy
26,131
+9,256
+55% +$362K ﹤0.01% 2868
2014
Q3 		$619K Buy
16,875
+225
+1% +$9.72K ﹤0.01% 3260
2014
Q2 		$771K Sell
16,650
-150
-0.9% -$6.67K ﹤0.01% 3040
2014
Q1 		$691K Buy
16,800
+400
+2% +$14.9K ﹤0.01% 3087
2013
Q4 		$626K Buy
16,400
+413
+3% +$12.7K ﹤0.01% 3236
2013
Q3 		$383K Sell
15,987
-1,013
-6% -$22.7K ﹤0.01% 3597
2013
Q2 		$289K Buy
+17,000
New +$245K ﹤0.01% 3598

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Royal Bank of Canada's ANIK Position: Q1 2026 in Review

Royal Bank of Canada reduced its Anika Therapeutics (ANIK) stake by 56% in Q1 2026, selling an estimated $5.33K and leaving 356 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #6400.

Royal Bank of Canada first reported a position in ANIK in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.11M in Q2 2019. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Royal Bank of Canada held 356 shares of Anika Therapeutics worth $5K as of Q1 2026.
  • Royal Bank of Canada sold 459 Anika Therapeutics shares in Q1 2026, an estimated $5.33K.
  • Anika Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6400 holding.
  • Royal Bank of Canada first reported a position in Anika Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Anika Therapeutics position peaked at $3.11M in Q2 2019.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.